Commissioner Hamburg as Congressional Witness: Mixed Success With GOP Thus Far
This article was originally published in RPM Report
Executive Summary
FDA Commissioner Margaret Hamburg has had some trouble at Congressional hearings, but she has made considerable headaway in her interactions with one key legislator, House Appropriations Committee Chair Rogers.
You may also be interested in...
Compounding: How Does FDA Expand Oversight Without Legislation?
After House Republicans indicate legislation expanding agency’s oversight of compounding is unlikely, FDA could consider other regulatory options, like changing internal policies or hoping a court clarifies its regulatory authority.
FDA’s Mermaid Problem: Makena and Pharmaceutical Half-Breeds
The Makena controversy is moving to court, and likely to a very unhappy ending for KV Pharma. But FDA’s decidedly unusual communications about compounding in the midst of that controversy may have longer term implications.
A Final Push For US Hepatitis C Eradication Plan In 2024
The Biden Administration is hoping that it can attach funding for a national hepatitis C ‘subscription’ program into the delayed fiscal 2024 appropriations bills.